GERMINAL MUTATIONS IN HOMOLOGOUS RECOMBINATION GENES IN A POPULATION OF PATIENTS WITH PANCREATIC CANCER: A SINGLE CENTRE EXPERIENCE

Objective. To estimate the frequency of germline mutations in homologous recombination genes in a population of patients with pancreatic cancer and to assess the possibility to predict the risk of mutation carriage based on the clinical and anamnestic data.

Materials and methods. The study included patients diagnosed with pancreatic cancer, blood samples of which were taken to detect clinically significant germline mutations in the BRCA1, BRCA2, CHEK2, BLM, NBS1, and PALB2 genes. Clinical data and family history data were collected for each patient.

Results. The study included 99 patients. Mutations in BRCA1 gene were detected in 4 % of cases, in CHEK2 gene – in 2 %. No mutations were detected in the BRCA2, as in BLM, NBS1, and PALB2 genes. Localization of primary tumor, presence of distant metastases, stage of disease, family history of malignant neoplasms did not correlate with the risk of BRCA1 mutation (p>0.05). The patient’s eligibility for NCCN criteria for BRCA1 gene mutation diagnosis proved to be a significant marker of germline mutation presence (p=0.043).

Conclusions. NCCN criteria for genetic testing are the best predictor of BRCA1 germline mutation in patients with pancreatic cancer.

1. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2016 godu (The state of oncological care for the population of Russia in 2016). Kaprin A. D., Starinskiy V. V., Petrova G. V. (eds.) Moscow: MNIOI im. P. A. Gertsena – filial FGBU NMITs radiologii Minzdrava Rossii, 2017. 236 p. (In Russ.).

2. Stathis A., Moore M. J. Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology. 2010. Vol. 7. No. 3. P. 163–172.

3. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.New England J. Medicine. 2011. Vol. 364. No. 19. P. 1817–1825.

4. Von Hoff D. D., Ervin T., Arena F. P., Chiorean E. G., Infante J., Moore M. et al. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. New England J. Medicine. 2013. Vol. 369. No. 18. P. 1691–1703.

5. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2017. CA: A Cancer J. Clinicians. Vol. 67. P. 7–30.

6. Kleeff J., Korc M., Apte M., La Vecchia C., Johnson C. D., Biankin A. V. et al. Pancreatic cancer.Nature Reviews Disease Primers. 2016. Vol. 2. P. 16022.

7. Noone A. M., Cronin K. A., Altekruse S F., Howlader N., Lewis D. R., Petkov V. I., Penberthy L. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiology and Prevention Biomarkers.2017. Vol. 26. P. 632–641.

8. Waddell N., Pajic M., Patch A. M., Chang D. K., Kassahn K. S., Bailey P. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015. Vol. 518. No. 7540. P. 495–501.

9. Holter S., Borgida, A., Dodd A., Grant R., Semotiuk K., Hedley D. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J. Clinical Oncology. 2015. Vol. 33. No. 28. P. 3124–3129.

10. Luo G., Lu Y., Jin K., Cheng H., Guo M., Liu Z. et al. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Review of Anticancer Therapy. 2015. Vol. 15. No. 10. P. 1223–1231.

11. Becker A. E., Hernandez Y. G., Frucht H., Lucas A. L. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J. Gastroenterology: WJG. 2014. Vol. 20. No. 32. P. 11182–11198.

12. Lucas A. L., Shakya R., Lipsyc M. D., Mitchel E. B., Kumar S., Hwang C. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clinical Cancer Research. 2013. Vol. 19. No. 13. P. 3396–3403.

13. Murphy K. M., Brune K. A., Griffin C., Sollenberger J. E., Petersen G. M., Bansal R. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17 %. Cancer Research. 2002. Vol. 62. No. 13. P. 3789–3793.

14. Lowery M. A., Kelsen D. P., Stadler Z. K., Kenneth H. Y., Janjigian Y. Y., Ludwig E. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The Oncologist. 2011. Vol. 16. No. 10. P. 1397–1402.

15. Blair A. B., Groot V. P., Gemenetzis G., Wei J., Cameron J. L., Weiss M. J. BRCA1 / BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J. American College of Surgeons.2018. Vol. 226. No. 4. P. 630–637.

16. Golan T., Kanji Z. S., Epelbaum R., Devaud N., Dagan E., Holter S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. British J. Cancer.2014. Vol. 111. No. 6. P. 1132–1138.

17. Nasedkina T.V., Gromyko O.E., Emel’yanova M.A., Ignatova E.O., Kazubskaya T.P., Portnoi S.M., Zasedatelev A.S., Lyubchenko L.N. Opredelenie germinal’nykh mutatsii v genakh BRCA1, BRCA2 i CHEK2 s ispol’zovaniem biochipov u bol’nykh rakom molochnoi zhelezy (Determination of germinal mutations in the BRCA1, BRCA2 and CHEK2 genes using biochips in patients with breast cancer). Molekulyarnaya biologiya. 2014. Vol. 48. No. 2. P. 243–250 (In Russ.).

18. Prokofyeva D., Bogdanova N., Bermisheva M., Zinnatullina G., Hillemanns P., Khusnutdinova E. et al. Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. Clinical Genetics. 2012. Vol. 82. No. 1. P. 100–101.

19. Daly M. B., Pilarski R., Berry M., Buys S. S., Farmer M., Friedman S. et al. NCCN Guidelines Insights: genetic / familial high-risk assessment: breast and ovarian, version 1.2018. J. National Comprehensive Cancer Network. 2018.

20. Shindo K., Yu J., Suenaga M., Fesharakizadeh S., Cho C., Macgregor-Das A. et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J. Clinical Oncology.2017. Vol. 35. No. 30. P. 3382–3390.

21. Lowery M. A., Wong W., Jordan E. J., Lee J. W., Kemel Y., Vijai J. et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. JNCI: J. National Cancer Institute.2018. Vol. 110. No. 10.

22. Kaufman B., Shapira-Frommer R., Schmutzler R. K., Audeh M. W., Friedlander M., Balmana J. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1 / 2 mutation. J. Clinical Oncology. 2014. Vol. 33. No. 3. P. 244–250.

23. Kashintsev A. A., Yanus G. A., Kokhanenko N. Yu., Moiseenko V. M., Khanevich M. D., Roman L. D. et al. Vstrechaemost’ mutatsii v genakh BRCA1 i BRCA2 u bol’nykh rakom podzheludochnoi zhelezy (The occurrence of mutations in the BRCA1 and BRCA2 genes in patients with pancreatic cancer). Sibirskii onkologicheskii zhurnal. 2013. Vol. 5. No. 59 (In Russ.).

24. Wallace A. J. New challenges for BRCA testing: a view from the diagnostic laboratory. European J. Human Genetics. 2016. Vol. 24. No. S1. P. S10.

25. Tyulyandina A., Gorbunova V., Khokhlova S., Kolomiets L., Filipenko M., Imyanitov E. et al. Profile of BRCA1 / BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study. AACR 2018 Proceedings. Abstracts 1–3027. No. 1241.

26. Bartsch D. K., Krysewski K., Sina-Frey M., Fendrich V., Rieder H., Langer P. Low frequency of CHEK2 mutations in familial pancreatic cancer. Familial Cancer. 2006. Vol. 5. No. 4. P. 305–308.

27. Dudley B., Karloski E., Monzon F. A., Singhi A. D., Lincoln S. E., Bahary N., Brand R. E. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer. 2018. Vol. 124. No. 8. P. 1691–1700.